---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-212597"
form_type: "8-K"
ticker: "BBIO"
cik: "0001743881"
company_name: "BridgeBio Pharma, Inc."
filed_at: "2022-08-04T23:59:59+00:00"
generated_at: "2026-06-24T04:20:13.154866+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# BridgeBio Q2 2022 revenue $73.7M, net loss $9.9M; cash $688.6M; pipeline data positive

## Summary
- Net loss attributable to common stockholders of $9.9M ($0.07 per share) vs $96.3M loss a year ago; revenue $73.7M from NULIBRY and licensing.
- Cash and equivalents $688.6M, providing runway into 2024; two-year deferral on senior debt principal repayment to Nov 2026.
- Positive Phase 2 interim data for infigratinib in achondroplasia: mean AHV increase 1.52 cm/year; added Cohort 5.
- Entered exclusive license with BMS for BBP-398 (SHP2 inhibitor) for up to $905M; received $90M upfront; sold PRV for $110M.
- Selected next-gen KRAS G12C dual inhibitor candidate; plans to begin clinical work mid-2023.

## SEC filing metadata
- accession: 0001193125-22-212597
- form_type: 8-K
- ticker: BBIO
- cik: 0001743881
- company_name: BridgeBio Pharma, Inc.
- filed_at: 2022-08-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1743881/000119312522212597/0001193125-22-212597-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1743881/000119312522212597/d365371d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-212597
- JSON: https://secwatch.observer/filing/0001193125-22-212597.json
- Plain text: https://secwatch.observer/filing/0001193125-22-212597.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.